In Vitro Expanded Autologous Invariant Natural Killer Cells in Cancer
The recruitment status of this study is unknown because the information has not been verified recently.
Verified February 2012 by Dana-Farber Cancer Institute.
Recruitment status was Active, not recruiting
Recruitment status was Active, not recruiting
Sponsor:
Beth Israel Deaconess Medical Center
Collaborator:
Dana-Farber Cancer Institute
Information provided by (Responsible Party):
F. Stephen Hodi, MD, Dana-Farber Cancer Institute
ClinicalTrials.gov Identifier:
NCT00631072
First received: February 28, 2008
Last updated: February 17, 2012
Last verified: February 2012
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of this research study is to determine whether we can purify and grow a population of cells from the participants blood (iNKT cells) and then safely give them back to the participant in increased numbers, and whether these cells will then stimulate the bodies own immune response against the cancer. These iNKT cells have been used in laboratory studies and information from these and other research studies suggest that increasing the number of these cells in the blood can stimulate the immune response against tumors.
| Condition | Intervention | Phase |
|---|---|---|
|
Malignant Melanoma |
Biological: in vitro expanded autologous invariant natural killer T cells Drug: GM-CSF |
Phase 1 |
| Study Type: | Interventional |
| Study Design: | Endpoint Classification: Safety/Efficacy Study Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | A Phase I Trial of in Vitro Expanded Autologous Invariant Natural Killer Cells in Cancer |
Resource links provided by NLM:
Further study details as provided by Dana-Farber Cancer Institute:
Primary Outcome Measures:
- To determine the feasibility of isolating and expanding in vitro autologous iNKT cells from cancer patients for therapeutic use. [ Time Frame: 2 years ] [ Designated as safety issue: No ]
- To assess the safety of treatment with in vitro expanded autologous iNKT cells alone, and in conjunction with GM-CSF. [ Time Frame: 2 years ] [ Designated as safety issue: Yes ]
Secondary Outcome Measures:
- To assess the biological activity of reinfused in vitro expanded autologous iNKT cells. [ Time Frame: 2 years ] [ Designated as safety issue: No ]
- To assess the biological activity of reinfused in vitro expanded autologous iNKT cells in conjunction with GM-CSF. [ Time Frame: 2 years ] [ Designated as safety issue: No ]
| Estimated Enrollment: | 24 |
| Study Start Date: | February 2008 |
| Estimated Primary Completion Date: | February 2013 (Final data collection date for primary outcome measure) |
Intervention Details:
Detailed Description:
-
Biological: in vitro expanded autologous invariant natural killer T cells
Administered in 3 equal doses by intravenous infusion on days 1, 15 and 29.
Other Name: iNKT
Drug: GM-CSF
Given subcutaneously once daily for 10 days beginning the second day of the second and third infusion
- The first step in the study will be to collect iNKT cells from the participants peripheral blood. For this procedure an intravenous catheter will be used to remove the blood. The white blood cells will be removed from the blood and the red blood cells and plasma will be returned to the participant (leukopheresis).
- We will then purify the iNKT cells from these collected white blood cells, and will grow them in culture plates in the lab under strictly controlled sterile conditions. This can take 4-6 weeks.
- If we are successful in growing the iNKT cells to large enough numbers, they will be divided into 3 equal doses. Participants will receive one dose of these cells by intravenous infusion every 2 weeks or days 1, 15 and 29. A blood sample will be taken immediately before each infusion, and at 1 and 4 hours after each infusion. Participants will be asked to return for blood samples on day 2, 3, 4 and 8 after infusion.
- The initial group of 3-6 participants will not receive any other therapy with the iNKT cell infusions. However, the subsequent group of 6 patients will in addition receive GM-CSF, which can further stimulate the immune system and may increase the effects of the iNKT cells. This medication is administered by subcutaneous injection and will be given daily for 10 days beginning the day of the second and third infusion.
- Participants will be on this research study for about 14 weeks, which includes the time for the cell purification and culture, treatment, and follow-up observation.
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Stage IV melanoma
- ECOG Performance Status 0-1
- Estimated life expectancy of 6 months or greater
- 18 years of age or older
- Adequate renal, hepatic and hematological function as outlined in protocol
- Adequate pulmonary and cardiac function as outlined in protocol
- Prior therapies must be discontinued at least 4 weeks prior to the leukopheresis to obtain iNKT cells. This does not include palliative surgery or radiation therapy, which may be used prior to leukopheresis or during the interval between leukopheresis and iNKT cell reinfusion
- Melanoma patients must not have brain metastases based on a negative MRI obtained within 4 weeks prior to screening, and must not have a history of brain metastases
- No other significant medical, surgical or psychiatric condition that, in the judgment of the PI, would interfere with compliance to the protocol regimen
Exclusion Criteria:
- Pregnant or nursing women
- Active systemic infection, positive HIV, HBV, or HCV serology, or immune deficiency disease
- Autoimmune disease that currently requires systemic therapy with immunosuppressive agents
- Known hypersensitivity to GM-CSF or DMSO
- Other active malignancy other than squamous cell or basal cell of the skin
Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00631072
Please refer to this study by its ClinicalTrials.gov identifier: NCT00631072
Locations
| United States, Massachusetts | |
| Beth Israel Deaconess Medical Center | |
| Boston, Massachusetts, United States, 02115 | |
| Dana-Farber Cancer Institute | |
| Boston, Massachusetts, United States, 02115 | |
Sponsors and Collaborators
Beth Israel Deaconess Medical Center
Dana-Farber Cancer Institute
Investigators
| Principal Investigator: | Steven Balk, MD, PhD | Beth Israel Deaconess Medical Center | |
| Principal Investigator: | F. Stephen Hodi, MD | Dana-Farber Cancer Institute |
More Information
No publications provided
| Responsible Party: | F. Stephen Hodi, MD, Principal Investigator, Dana-Farber Cancer Institute |
| ClinicalTrials.gov Identifier: | NCT00631072 History of Changes |
| Other Study ID Numbers: | 06-432 |
| Study First Received: | February 28, 2008 |
| Last Updated: | February 17, 2012 |
| Health Authority: | United States: Food and Drug Administration |
Keywords provided by Dana-Farber Cancer Institute:
|
iNKT in vitro autologous iNKT |
Additional relevant MeSH terms:
|
Melanoma Neoplasms Neoplasms by Histologic Type Neoplasms, Germ Cell and Embryonal |
Neoplasms, Nerve Tissue Neuroectodermal Tumors Neuroendocrine Tumors Nevi and Melanomas |
ClinicalTrials.gov processed this record on February 25, 2015